Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,913 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer.
Tanaka S, Uchino J, Yokoi T, Kijima T, Goto Y, Suga Y, Katayama Y, Nakamura R, Morimoto K, Nakao A, Hibino M, Tani N, Takeda T, Yamaguchi H, Tachibana Y, Takumi C, Hiraoka N, Takeshita M, Onoi K, Chihara Y, Taniguchi R, Yamada T, Matsui Y, Hiranuma O, Morimoto Y, Iwasaku M, Tokuda S, Kaneko Y, Yamada T, Takayama K. Tanaka S, et al. Among authors: yamaguchi h. Diagnostics (Basel). 2022 Feb 6;12(2):423. doi: 10.3390/diagnostics12020423. Diagnostics (Basel). 2022. PMID: 35204513 Free PMC article.
Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
Yamaguchi H, Soda H, Nakamura Y, Takasu M, Tomonaga N, Nakano H, Doi S, Nakatomi K, Nagashima S, Takatani H, Fukuda M, Hayashi T, Tsukamoto K, Kohno S. Yamaguchi H, et al. Cancer Chemother Pharmacol. 2011 Feb;67(2):331-8. doi: 10.1007/s00280-010-1325-x. Epub 2010 Apr 17. Cancer Chemother Pharmacol. 2011. PMID: 20401612 Clinical Trial.
A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer.
Ikeda T, Fukuda M, Nakamura Y, Kinoshita A, Senju H, Nakano H, Kitazaki T, Ogawara D, Taniguchi H, Motoshima K, Yamaguchi H, Nakatomi K, Shimada M, Nagashima S, Tsukamoto K, Kohno S; Nagasaki Thoracic Oncology Group. Ikeda T, et al. Among authors: yamaguchi h. Cancer Chemother Pharmacol. 2014 Sep;74(3):497-502. doi: 10.1007/s00280-014-2527-4. Epub 2014 Jul 18. Cancer Chemother Pharmacol. 2014. PMID: 25034978 Free article. Clinical Trial.
Dynamics of blood neutrophil-related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non-small cell lung cancer: A hypothesis-generating study.
Soda H, Ogawara D, Fukuda Y, Tomono H, Okuno D, Koga S, Taniguchi H, Yoshida M, Harada T, Umemura A, Yamaguchi H, Mukae H. Soda H, et al. Among authors: yamaguchi h. Thorac Cancer. 2019 Feb;10(2):341-346. doi: 10.1111/1759-7714.12952. Epub 2018 Dec 23. Thorac Cancer. 2019. PMID: 30582295 Free PMC article. Clinical Trial.
Phase II trial of a non-platinum triplet for patients with advanced non-small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA.
Takemoto S, Nakamura Y, Gyoutoku H, Senju H, Ogawara D, Ikeda T, Yamaguchi H, Kitazaki T, Nakano H, Nakatomi K, Tomari S, Sato S, Nagashima S, Fukuda M, Mukae H. Takemoto S, et al. Among authors: yamaguchi h. Thorac Cancer. 2019 Mar;10(3):452-458. doi: 10.1111/1759-7714.12958. Epub 2019 Jan 9. Thorac Cancer. 2019. PMID: 30628188 Free PMC article. Clinical Trial.
Phase II study of ramucirumab and docetaxel for previously treated non-small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study.
Takemoto S, Fukuda M, Yamaguchi H, Ikeda T, Akagi K, Tomono H, Umeyama Y, Dotsu Y, Taniguchi H, Gyotoku H, Senju H, Kitazaki T, Nakatomi K, Nagashima S, Fukuda M, Kinoshita A, Soda H, Mukae H. Takemoto S, et al. Among authors: yamaguchi h. Thorac Cancer. 2020 Feb;11(2):389-393. doi: 10.1111/1759-7714.13279. Epub 2019 Dec 18. Thorac Cancer. 2020. PMID: 31851428 Free PMC article.
Efficacy of S-1 after pemetrexed in patients with non-small cell lung cancer: A retrospective multi-institutional analysis.
Takemoto S, Akagi K, Ono S, Tomono H, Honda N, Suyama T, Umeyama Y, Dotsu Y, Taniguchi H, Ogawara D, Senju H, Gyotoku H, Sugasaki N, Yamaguchi H, Nakatomi K, Fukuda M, Mukae H. Takemoto S, et al. Among authors: yamaguchi h. Thorac Cancer. 2021 Sep;12(17):2300-2306. doi: 10.1111/1759-7714.14055. Epub 2021 Jul 13. Thorac Cancer. 2021. PMID: 34255933 Free PMC article.
Fibrosis and inflammatory activity in noncancerous tissue and mitotic index of cancer tissue in patients with hepatocellular carcinoma: relationship to clinicopathological factors and prognosis after hepatic resection.
Nanashima A, Tanaka K, Yamaguchi H, Shibasaki S, Morino S, Yoshinaga M, Sawai T, Nakagoe T, Ayabe H. Nanashima A, et al. Among authors: yamaguchi h. Dig Dis Sci. 2003 Aug;48(8):1517-22. doi: 10.1023/a:1024759606402. Dig Dis Sci. 2003. PMID: 12924646
Phase II study of nedaplatin and amrubicin as first-line treatment for advanced squamous cell lung cancer.
Taniguchi H, Yamaguchi H, Dotsu Y, Shimada M, Gyotoku H, Senju H, Takemoto S, Kitazaki T, Fukuda M, Ogawara D, Soda H, Nakatomi K, Sugasaki N, Kinoshita A, Nagashima S, Ikeda T, Nakamura Y, Sakamoto N, Obase Y, Fukuda M, Mukae H. Taniguchi H, et al. Among authors: yamaguchi h. Thorac Cancer. 2019 Sep;10(9):1764-1769. doi: 10.1111/1759-7714.13134. Epub 2019 Jul 16. Thorac Cancer. 2019. PMID: 31309738 Free PMC article. Clinical Trial.
4,913 results